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Abstract
Transposable Elements (TEs) are mobile genetic elements whose sequences constitute nearly half of the human
genome. Each TE copy can be present in hundreds to thousands of locations within the genome, complicating the
genetic and genomic studies of these highly repetitive sequences. The recent development of better tools for
evaluating TE derived sequences in genomic studies has enabled an increasing appreciation for the contribution of
TEs to human development and disease. While some TEs have contributed novel and beneficial host functions, this
review will summarize the evidence for detrimental TE activity in neurodegenerative disorders. Much of the
evidence for pathogenicity implicates endogenous retroviruses (ERVs), a subset of TEs that entered the genome by
retroviral infections of germline cells in our evolutionary ancestors and have since been passed down as a
substantial fraction of the human genome. Human specific ERVs (HERVs) represent some of the youngest ERVs in
the genome, and thus are presumed to retain greater function and resultant pathogenic potential.
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Background
Transposable elements (TEs) represent a vast array of
genomic sequences that have (or once had) the ability to
mobilize from one location in the genome to another.
Several excellent reviews explain the general features and
behavior of transposable elements [1–3]. Two major
classes of TEs exist: Class I TEs, also called retrotranspo-
sons, utilize an RNA intermediate that is reverse
transcribed before genomic reinsertion; Class II TEs, or
DNA transposons, move via excision from one genomic
location and insertion into another. In most genomes,
Class I retrotransposons represent the vast majority of TE
derived sequences since new copies accumulate with each
transposition event. Retrotransposons can further be
subdivided into a few major families: the long interspersed
nuclear element (LINE) class of fully autonomous retroe-
lements (21% of the human genome [4] the SINE class of
shorter retroelements that rely on LINE encoded proteins
for mobilization (13% [4]), and the long terminal repeat
(LTR) retrotransposons that include endogenous retrovi-
ruses (ERV, 8%) [4]. ERV sequences [1–3, 5] represent an
interesting subclass of TEs that derive from retroviral
infections of germline cells in our ancestors, which were
then endogenized and passed along to future generations.
Some of the evolutionarily youngest (ie, most recently
inserted) TEs are present only in the genomes of humans
and closely related primates, and are dubbed human ERVs
(HERVs).
While nearly half of the human genome is composed
of TE derived sequences [4], almost all of these
sequences have lost the ability to mobilize to new loca-
tions. Only the human specific LINE-1 (L1) element,
L1HS, present in full form in 100–180 locations in the
human genome [6–9], retains the ability to autono-
mously mobilize and create new insertional mutations.
Other TEs have less autonomous levels of function,
varying from the simple ability to be transcribed into
RNAs, the ability to make functional proteins, the ability
to reverse transcribe their RNA transcripts into cDNA,
and, finally, the ability to attempt genomic insertion.
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Thus, while many studies of TEs focus on detection of
new transposition events (hopping), their novel func-
tional activities can be broadly classified based on
whether they engender RNA expression, cDNA gener-
ation, and/or production of functional proteins. Each TE
insertion encodes for a different level of activity due to
mutations within the TE sequence that may render pro-
tein or regulatory sequences non-functional. Thus it is
important to be specific about the relative ability for
each TE copy to affect cellular function, following the
detection of aberrant TE accumulation.
Mechanisms for TE-mediated cellular stress
The most commonly implicated pathogenic functions of
TEs result from direct mutagenic effects of newly trans-
posed insertions. As stated above, only a subset of L1HS
elements are fully capable of mobilizing in vivo, creating
de novo insertional mutations at a rate of about one
L1HS germline insertion per 100 individuals [10]. In
addition, L1HS machinery can facilitate mobilization of
other non-autonomous TE families, including Alu and
SVA (SINE/VNTR/Alu), some of which are known to be
polymorphic (representing relatively recent insertion
events) with estimated transposition rates of about 0.04
and 0.001 new insertions per generation, respectively
[10], and an overall retrotransposition rate of about 0.02
germline events per generation. L1HS can also mobilize
in certain somatic tissues, with a transposition rate esti-
mated at about 0.04–13 insertions per cell in neurons
[11–15]. This cell-type-specific mosaicism could explain
reports suggesting that de novo transposon insertions
are more commonly found in brain compared to other
somatic tissues [11, 16, 17] and that neuronal cells are
more permissive to retrotransposition [5, 11]. However,
a comprehensive study comparing somatic transposition
rates across healthy human tissues has not been com-
pleted. In contrast, somatic retrotransposition is much
more common in human cancers [18] with an estimated
rate of 4–100 de novo insertions per tumor in many
tumor types of different tissues [8, 19, 20]. The potential
for similarly higher somatic rates has not been fully ex-
plored in disease settings outside of cancer.
In contrast to the relatively rare events of detectable de
novo insertion, the most common molecular function of
TEs is to generate RNAs. Many genomic TEs retain tran-
scriptional regulatory sequences that can direct the gener-
ation of RNA transcripts, potentially including chimeric
sequences downstream of the TEs themselves [21–23]. A
subset of ERVs and L1 elements contain bidirectional pro-
moters [21] capable of generating long double-stranded
RNAs (dsRNAs) [24]. Moreover, the density of sense and
anti-sense copies of TEs embedded within introns and un-
translated regions creates the potential to generate dsRNA
segments from adjacent inverted repeats (IR), with Alu
elements being the most common source of IR derived
dsRNAs [25, 26]. When not properly degraded or resolved
by adenosine deaminase, RNA specific (ADAR) editing
complexes, long dsRNAs from retroelements can be recog-
nized by DExD/H-Box Helicase 58 (DDX58/RIG-I), which
alerts the antiviral surveillance machinery and activates in-
flammatory responses via interferon mediated Toll-Like
Receptor pathways and tumor necrosis factor (TNF) alpha
[24]. In addition, if the TE RNAs are produced from a
locus that encodes a functional reverse transcriptase, there
exists the possibility for cytosolic cDNA production, which
alerts a separate interferon-mediated inflammatory path-
way downstream of cyclic GMP-AMP synthase (CGAS)
and stimulator of interferon genes (STING/TMEM173)
[24], as has previously been seen in aging mice expressing
active LINE1 retrotransposons [27, 28]. Finally, some of
the proteins generated from full length TE transcripts are
directly 1) immunogenic in certain cancers [29, 30], and 2)
cytotoxic in the case of HERV derived Envelope proteins
in neurodegenerative diseases [31, 32].
In the case of neurological diseases, the best evidence for
differential TE activity has come from detection of elevated
TE-associated RNAs, cDNAs, and proteins in patient sam-
ples. While specific TE derived products have different
consequences, the most commonly implicated pathogenic
mechanisms are an inflammatory response to dsRNAs
and/or cDNAs, or a direct cytotoxic response to specific
proteins. The rest of this review will focus on the evidence
for TE activity in four neurological disorders that have
both evidence of TE products in diseased patient tissues as
well as model organism support for pathogenicity down-
stream of TE activity. These include Aicardi-Goutieres
syndrome (AGS), Multiple Sclerosis (MS), Amyotrophic
Lateral Sclerosis (ALS), and Alzheimer’s Disease (AD). The
diseases have been roughly divided into those that show
evidence of retrotransposon induced general inflammation
(AGS and MS) and those that show neurotoxic effects of
retrotransposon products (ALS and AD). Figure 1 summa-
rizes the evidence implicating retrotransposons in each of
these diseases, which will be discussed in detail in the fol-
lowing sections. Table 1 provides a list of all named genes
discussed in this review, both those that contribute to
disease as well as those involved generally in retro-
transposon regulation.
Evidence for retrotransposon activity in Aicardi-
Goutieres syndrome
Aicardi-Goutieres Syndrome (AGS) (OMIM 225750) is a
genetic disorder caused by abnormal activation of the
type I interferon pathway. The disorder typically mani-
fests in infants within their first year of life and is
characterized by general inflammation. Other clinical
symptoms include severe encephalopathy with dystonia,
spasticity, intermittent sterile pyrexia, basal ganglia
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calcifications, leukodystrophy, and a lymphocytic CSF
pleocytosis [24, 33, 34].
AGS can be caused by mutations in the three prime re-
pair exonuclease 1 (TREX1) [35], SAM and HD domain
containing deoxynucleoside triphosphate triphosphohy-
drolase 1 (SAMHD1) [36], adenosine deaminase RNA
specific (ADAR) [37], interferon induced with helicase C
domain 1 (IFIH1) [38] genes, or subunits of the RNase H2
complex [39]. Intriguingly, these genes are involved in the
modulation of cytosolic nucleic acid species, and patho-
genic mutations lead to increased type I interferon activity
that mimics an innate response against viral infection in
nearly all AGS patients [40, 41]. The involvement of the
aforementioned genes suggests that endogenous nucleic
acid products could accumulate, and become recognized
as foreign in AGS, triggering an innate immune response
against the host.
Retrotransposons are implicated as a source of
immunogenic endogenous nucleic acid products in
AGS, though the two sub-classes implicated, L1 and
Alu, appear to operate through different mechanisms.
Both SAMHD1 and TREX1 alter LINE-1 activity in
human cells and mouse models. Depletion of TREX1
results in the accumulation of reverse-transcribed
cytosolic single-stranded DNA fragments containing
L1 sequences, and causes an increase in L1 retrotran-
sposition events in reporter assays [36, 37, 42, 43].
This is replicated by pathogenic TREX1 variants
found in AGS patients [42, 44]. The exonuclease ac-
tivity of TREX1 appears dispensable for repressing L1
activity, with TREX1 associating with and depleting
the ORF1p protein via proteasome-mediated proteoly-
sis [42]. L1 RNA is upregulated in TREX1-deficient
astrocytes but not in neurons, and the higher reverse
Fig. 1 Transposable element (TE) activity in four neurological disorders: Aicardi-Goutieres Syndrome (AGS), Multiple Sclerosis (MS), Amyotrophic
Lateral Sclerosis (ALS), and Alzheimer’s Disease (AD). In AGS and MS, TE nucleic acids and endogenous retroviral (ERV) proteins may be driving
inflammation through innate immune sensing pathways. In ALS and AD, the pathogenic effects of TEs appear more localized to either motor
neurons (in ALS), and hippocampal or cortical neurons (in AD). Innate immune pathways are activated by double-stranded RNAs and cDNAs
produced by TE/ERV transcription and reverse transcription, respectively; this is the primary mechanism implicated in AGS, and could be at play in
the other disorders. In addition, envelope proteins from the HERVW and HERVK class have been shown to be neurotoxic when expressed, and
implicated in MS and ALS, respectively. Increased mobilization of fully competent TEs has not been convincingly demonstrated for any
neurodegenerative disorder, though this mechanism has not been fully tested
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transcriptase activity (perhaps mediated by accumula-
tion of single-stranded DNA fragments) activates the
secretion of interferon from the astrocytes that leads
to neurotoxicity [38, 43].
Other proteins implicated in AGS can regulate L1
elements. Depletion of SAMHD1 by siRNA leads to
increased L1 retrotransposition in reporter assays
[1–3, 45, 46], which is mimicked by mutations in
the HD domain or the allosteric GTF binding region,
but not from the loss of its dNTP nuclease activity
[45, 47]. The subcellular localization of SAMHD1
correlates with its capacity for L1 regulation. Mu-
tants that preferentially localize to the nucleus ex-
hibit defective suppression [48], while expression of
a cytoplasmically restricted SAMHD1 in HEK293T
(through mutation of its nuclear localization signal)
Table 1 A Glossary of all gene names cited in this review including the official symbol, common names, known function, and
potential association with each of the four neurodegenerative diseases: Aicardi-Goutieres Syndrome (AGS), Amyotrophic Lateral
Sclerosis (ALS), Alzheimer’s Disease (AD), and Multiple Sclerosis (MS). The name of the associated neurodegenerative disease is
enclosed in parentheses if a disease-associated mutation has not been identified in the Online Mendelian Inheritance in Man
(OMIM) database, but has still been implicated due to other experimental evidence discussed in this review
Gene
symbol
Gene name Synonym Known function Associated
disordera
ADAR Adenosine Deaminase, RNA Specific Enzyme converting adenosine to inosine by deamination AGS
APP Amyloid Beta Precursor Protein A-beta Cell surface receptor with roles in neurite growth, neuronal
adhesion and axonogenesis
AD
ARC Activity Regulated Cytoskeleton Associated
Protein
Regulator of synaptic plasticity that mediate intercellular RNA
transfer in the nervous system.
(AD)
ASH1L ASH1 Like Histone Lysine Methyltransferase ASH1 Histone methyltransferase specifically methylating “Lys-36” of
histone H3
BPTF Bromodomain PHD Finger Transcription
Factor
Histone-binding component of nucleosome-remodeling factor
C9ORF72 C9orf72-SMCR8 Complex Subunit
Chromosome 9 Open Reading Frame 72
Component of the C9orf72-SMCR8 complex that has guanine
nucleotide exchange factor activity and regulates autophagy
ALS
CGAS Cyclic GMP-AMP Synthase Catalyzes formation of cyclic GMP-AMP (cGAMP) from ATP and
GTP
DDX58 DExD/H-Box Helicase 58 RIG-I Cytoplasmic sensor of viral nucleic acids
ERVW-1 Endogenous Retrovirus Group W Member 1,
Envelope
Induces trophoblast fusion and formation of a placental
syncytium
(MS)
ERVW-2 Endogenous Retrovirus Group W Member 2 None reported (MS)
IFIH1 Interferon Induced With Helicase C Domain 1 MDA5 Cytoplasmic sensor of viral nucleic acids AGS
IRF1 Interferon Regulatory Factor 1 Activator of genes involved in both innate and acquired
immune responses
PIWIL1 Piwi Like RNA-Mediated Gene Silencing 1 Endoribonuclease that represses transposable elements in
postnatal germ cells
RNASEH2A Ribonuclease H2 Subunit A Catalytic subunit of RNase H2 that degrades RNA of RNA:DNA
hybrids
AGS
RNASEH2B Ribonuclease H2 Subunit B Non catalytic subunit of RNase H2 AGS
RNASEH2C Ribonuclease H2 Subunit C Non catalytic subunit of RNase H2 AGS
SAMHD1 SAM And HD Domain Containing
Deoxynucleoside Triphosphate
Triphosphohydrolase 1
Host restriction factor involved in defense response to virus AGS
TARDBP TAR DNA Binding Protein TDP-43 RNA-binding protein involved in various steps of RNA
biogenesis and processing
ALS
TMEM173 Transmembrane Protein 173 STING Receptor that detects cytosolic nucleic acids
TNF Tumor Necrosis Factor TNF-
alpha
Pro-inflammatory cytokine
TNFSF14 Tumor Necrosis Factor Superfamily Member
14
LIGHT TNF superfamily ligand
TREX1 Three Prime Repair Exonuclease 1 3′-to-5′ DNA exonuclease AGS
aThe associated disorder is enclosed in parentheses if the gene-disorder association is not listed in OMIM, but has been implicated due to other experimental
evidence in one of the studies discussed
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enhances L1 suppression. The SAMHD1 protein also
associates with L1 ORF2p [47, 48] and reduces its
expression, leading to lower reverse transcriptase
activity [45, 48]. This is likely mediated by the
formation of stress granules, which sequester L1
proteins [46]. ADAR and RNaseH2 complexes may
also regulate L1 - depletion of ADAR increases L1
retrotransposition, for example, but the molecular
mechanism remains unclear [49].
The role of Alu elements as immunogenic endogenous
nucleic acid products in AGS differs from L1. Whereas
L1 reverse transcriptase is implicated in activating the
type I interferon pathway, the presence of Alu embedded
in cellular transcripts appears to directly cause the in-
flammatory response. Genome-wide characterization of
ADAR adenosine to inosine (A-to-I) editing revealed en-
richment at Alu elements located at 3′ UTR or intronic
regions of a cellular transcript [50]. Many of these Alu
elements are in an inverted repeat configuration less
than 1 kb apart on a single cellular transcript [51]. In the
absence of ADAR, these Alu elements no longer show
A-to-I editing, and strongly associate with the cytosolic
dsRNA sensor, IFIH1 (also known as melanoma differen-
tiation-associated gene 5 or MDA5), resulting in the ac-
tivation of the interferon pathway [42, 44, 51]. IFIH1
mutations in AGS patients show increased affinity for
endogenous transcripts with inverted Alu repeats, des-
pite ADAR-mediated A-to-I editing [42, 51]. The identi-
fication of Alu inverted repeats as a possible endogenous
trigger for AGS has solidified a model where ADAR
serves to edit “self” RNA at regions of high secondary
structures to prevent them from being recognized as for-
eign by IFIH1 [50–55].
The observation that reverse transcriptase activity is
increased by depletion of TREX1 and SAMHD1 inspired
researchers to try reverse transcriptase inhibitors (RTIs)
to treat AGS. In a Trex1 mouse model, one study
showed amelioration of inflammatory myocarditis by the
RTIs Truvada and Viramune [56], while another study
failed to demonstrate a reduction in interferon response
in the same model system [57]. Despite these conflicting
results in mouse models, a pilot study of three reverse
transcriptase inhibitors (abacavir, lamivudine, and zi-
dovudine) showed a reduced interferon response in AGS
patients as measured by expression of six interferon
stimulated genes [58]. Though the study was small (8
patients) and open label/un-blinded, they were able to
detect a reduction in interferon activity in blood and
CSF samples as well as increased cerebral blood flow for
all patients during the 12 months they were receiving
therapy [58], suggesting this will be a promising thera-
peutic strategy. Further studies are required to deter-
mine if the pathogenic capacity of retrotransposons in
AGS is restricted to the generation of endogenous
immunogenic molecules, or might also be mediated by
their retrotransposition.
Finally, in addition to the evidence for retrotransposon-
mediated contributions to AGS pathophysiology, two
studies demonstrated much higher rates of micronuclei
formation in the Rnaseh2b mutant mouse model of AGS
[59, 60]. Micronuceli are membrane-enclosed cytosolic
structures containing fragments of genomic DNA not in-
corporated into the daughter nuclei during mitosis, arising
as a consequence of DNA damage and/or aneuploidy. The
amount of micronuclear DNA in the Rnaseh2b mutants
correlated with cGAS and STING pathway activation, sug-
gesting that generic DNA, and not just retrotransposon
cDNA, may induce auto-inflammatory mechanisms in this
AGS mouse model. Moreover, at least two studies [59]
have shown that RNASEH2B appears to be required for
L1 transposition, suggesting that L1 cDNA is unlikely to
increase in the absence of RNASEH2B, and may not be
the trigger for auto-inflammation for this particular gene
mutation.
Evidence for HERV activity in MS
Multiple sclerosis (MS) (OMIM 126200) is a chronic CNS
disorder involving autoimmune-mediated demyelination.
Patients most often present with focal neurological deficits
(e.g. vision loss, altered/loss of sensation, motor deficits, or
cognitive impairment) that localize to distinct areas (“pla-
ques”) of demyelination in the brain, spinal cord, and/or
optic nerves. The deficits may partly or fully resolve over
the ensuing weeks, with later “relapses” involving new defi-
cits in different CNS regions (“relapsing-remitting” MS), or
there may be a more gradual progressive deterioration
without improvement (“primary progressive MS”). Cases
with a relapsing-remitting course can also later transform
into a progressive course without improvement between
discrete attacks (“secondary progressive MS”) [61]. Genetic
association studies have identified over 200 risk loci for MS,
the strongest of which lies in the major histocompatibility
complex (MHC) locus [62].
There is evidence that retrotransposons, particularly hu-
man endogenous retroviruses (HERVs), may be associated
with the development and/or progression of MS. Cerebro-
spinal fluid (CSF) from MS patients has been shown to
contain viral particles and reverse transcriptase activity
[63]. Subsequent studies identified retroviral-like se-
quences in both CSF [64, 65] and serum [66, 67] of MS
patients, with high homology to the human endogenous
retrovirus group W (HERVW) [68]. Immunohistochemis-
try of MS lesions in postmortem CNS tissues show that
the envelope gene of HERVW (HERVW-Env) is upregu-
lated both at the RNA and protein levels in activated
microglia and reactive astrocytes, but not in neurons or
oligodendrocytes [31, 67, 69, 70]. The HERVW-Env pro-
tein induces a pro-inflammatory response in human fetal
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astrocytes [31], likely through TLR4 [71], and also acti-
vates genes associated with endoplasmic reticulum stress
[72]. Furthermore, soluble factors released from primary
rat astrocyte cultures overexpressing HERVW-Env reduce
the production of myelin in cultured oligodendrocytes
[72] and eventually lead to oligodendrocyte damage and
death [31]. HERVW-Env proteins have also been detected
in peripheral blood mononuclear cells (PBMC) [73, 74],
serum and cerebral spinal fluids [75] of MS patients. MS
patients with active disease (ie, those exhibiting worsening
neurological dysfunction) express more HERVW-Env pro-
teins on the cell surface of PBMCs than healthy control
subjects or MS patients in remission [74]. Indeed, the
transcript levels of HERVW-Env in PBMCs, as measured
by RT-PCR, correlates with disease severity [76]. In con-
trast to these studies, another group failed to find consist-
ently elevated HERVW-Env transcripts in MS patient
tissues [77, 78], and an additional study has raised con-
cerns about the early qPCR assays used for HERVW tran-
script detection [79].
In addition to full length HERVW transposable ele-
ments, two genes derived from HERVW-Env, ERVW-1
and ERVW-2, have also been identified in the human
genome, and their aberrant expression could potentially
contribute to the accumulation of HERVW-Env tran-
scripts and protein. However, these genes lack other
components that are likely necessary to generate inflam-
matory dsRNAs and cDNAs [77, 80–83]. While they
share high sequence homology to the HERVW-Env tran-
scripts reported in MS [31, 69], evidence for pathogen-
icity is presently lacking.
The association between HERVW-Env protein and MS
has led to the development of a monoclonal antibody
(GNbAC1), currently in clinical trials as a potential thera-
peutic for the disease. A phase I study of 33 healthy indi-
viduals indicate that GNbAC1 is well tolerated [84]. A
phase IIa study of 10 patients shows a decrease in p38
phosphorylation in monocytes (a readout of decreased
TLR4 signaling) after treatment with GNbAC1 over 6
months, without adverse effects on the normal functions
of the immune system [85]. Another phase IIa study also
shows a reduction of HERVW transcripts in individuals
after 6 months of GNbAC1 treatment compared with pla-
cebo (5 MS patients in each group) [86]. No adverse ef-
fects, such as inadvertent increase in disease activity or
immunosuppression, were observed in the GNbAC1
treated individuals either at the end of the 6month period
[86], nor in the 6months afterwards [87]. However, while
subsequent results showed a potential association with
remyelination in patients on GNbAC1, there was no signal
of immunomodulatory effects of the treatment, raising
questions as to the mode of action [88].
HERVW-Env has also been implicated in Chronic
Inflammatory Demyelinating Polyradiculoneuropathy
(CIDP), which causes demyelination in the peripheral
nervous system. HERVW-Env is observed in nerve
biopsies of CIDP patients, localizing to the myelin
sheath and neurilemma [89]. In vitro studies show
that overexpression of HERVW-Env induces IL6 and
CXCL10 expression (typically elevated in CIDP
patients) through the TLR4 receptor in primary
human Schwann cell cultures [89]. These parallels to
findings in MS suggest that GNbAC1 could be con-
sidered as a novel therapy in CIDP as well.
In addition to HERVW, human endogenous retrovirus
group H (HERVH) has also been implicated in MS.
Association studies identified linkage disequilibrium of sin-
gle nucleotide polymorphisms near a HERV-Fc1 (HERVH
subtype) locus on the X-chromosome in MS patients [90].
While HERVH levels have not been measured in demyeli-
nated tissues, active MS patients exhibit a significant
increase in HERV-Fc1 RNA in serum as compared to
healthy control subjects, and MS patients in remission also
have increased HERV-Fc1 RNA in monocytes compared to
unaffected individuals [91].
In summary, there is substantial evidence to suggest an
association between elevation of HERV transcripts/enve-
lope protein and MS. However, there is still uncertainty as
to whether HERV expression is a cause or consequence of
the neuroinflammatory response. Although HERVW-Env
induces a pro-inflammatory response in astrocytes [31],
its expression is also increased in response to inflamma-
tion, leading to difficulties in establishing causality [72].
Furthermore, elevated expression of particular HERVs
might lead to global increases in other retrotransposon
transcripts and/or proteins, potentially acting as another
mechanism of cellular damage. Given the multifactorial
etiology of MS, HERVW-Env (and perhaps HERVs in gen-
eral) may both contribute to the initial development of
MS in some cases as well as amplifying any inflammatory
responses to other initiating insults in the glial population,
leading to cell non-autonomous damage in the central
nervous system.
Evidence for retrotransposon activity in ALS
Amyotrophic lateral sclerosis (ALS) (OMIM 105400) is a
fatal neurodegenerative disorder that is characterized by
progressive loss of upper and lower motor neurons.
Patients initially present with either muscle weakness of
the limbs or speech/swallowing difficulties, depending
on the site of onset (limb or bulbar respectively). Paraly-
sis progressively spreads throughout the motor system,
affecting critical body functions and eventually resulting
in death [92]. Genetic association studies have identified
about 20 ALS-associated genes that can be collectively
grouped into four main disease pathways: RNA metabol-
ism, protein homeostasis, cytoskeletal components, and
mitochondrial function [93]. These mutations are most
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commonly detected in the ~ 10% of ALS patients with a
positive family history, though some are also found in
sporadic (sALS) patients, such as the C9orf72 expansion
which is detected in 5–10% of sALS. However, most
ALS patients present without a family history of disease
nor known ALS-associated mutations [94]. Despite the
relatively low genetic heritability for this disease, nearly
all ALS patients show aggregates of an RNA-binding
protein, TARDBP/TDP-43 (TAR DNA binding protein),
that pathologically accumulates in motor neurons of the
motor cortex and spinal cord [95].
Several recent studies have implicated HERV retrotran-
sposons in the development of ALS. Serum from ALS
patients shows increased reverse transcriptase (RT) activ-
ity compared to healthy controls [96–99], though there is
some evidence of elevated RT activity in the serum of ALS
patient relatives [97]. Studies of RT activity in the cerebro-
spinal fluids of ALS patients either failed to identify a
significant increase [98], or only in a very small subset of
patients (1/25) [99]. Immunohistochemistry of post-mor-
tem brains of ALS patients uncovered an increase in hu-
man endogenous virus – group K (HERVK) transcripts
[100, 101], and follow-up studies showed the HERVK re-
verse transcriptase (HERVK-RT) protein localized within
the nucleus and cytoplasmic foci of cortical pyramidal
neurons, and is significantly more abundant in the pre-
frontal and motor cortices of ALS patients compared to
unaffected individuals [100]. HERVK envelope protein
(HERVK-Env) was also detected in the cytoplasm of pyr-
amidal neurons in the cortex and in the anterior neural
horn of the spinal cord in ALS patients, but not in glial
cells or white matter [101]. Enzyme-linked immunosorb-
ent assay (ELISA) also detected elevated levels of HERVK-
Env peptide fragments in the sera and cerebrospinal fluids
of ALS patients, compared to healthy controls and
patients with other neurological disorders (e.g. Alzhei-
mer’s and MS) [75]. The levels of HERVK-Env peptides in
both sera and cerebrospinal fluids also correlated with
poorer ALS Functional Rating Scale – revised score
(ALSFRS-R), suggesting a potential marker for ALS dis-
ease progression [75].
In vitro and in vivo overexpression of HERVK-Env re-
sults in significant dendritic defects and neuronal cell
death, with a transgenic mouse model showing reduction
of corticospinal motor neurons, decreased motor cortex
thickness and neuronal loss of upper and lower motor
neurons, decreased motor cortex thickness, limb muscle
atrophy and denervation [101]. These animals also
develop progressive motor dysfunction, akin to ALS
patients [101]. In transgenic Drosophila models, upregula-
tion of transposable elements (including gypsy, an inverte-
brate LTR retrotransposon encoding an ERV-like envelope
protein) was seen in transgenic Drosophila models that
over-express the ALS-associated gene TARDBP/TDP-43.
In these models, aggregation of TDP-43 protein and con-
sequent TE upregulation lead to both neuronal and glial
cell death, which could be ameliorated by knockdown of
the most abundant Drosophila TE, gypsy [102].
The molecular mechanism regulating HERVK expres-
sion in ALS remains unresolved. Pro-inflammatory
signals, such as TNF alpha and TNF superfamily member
14 (TNFSF14/LIGHT), have been shown to activate
HERVK expression levels in vitro in neurons and astro-
cytes, respectively. This is likely mediated by Interferon
Regulatory Factor 1 (IRF1) and NF-kappa-B signaling,
which were shown to be upregulated in vitro upon
addition of the aforementioned pro-inflammatory signals,
and upregulated and nuclear enriched in HERVK positive
pyramidal neurons in the cortex of ALS patients [103].
However, it remains unclear if HERVK expression is initi-
ated or merely amplified by neuroinflammation. Another
candidate implicated in HERVK regulation in ALS is
TARDBP/TDP-43 [104]. The first hints of possible inter-
action between HERVK and TDP-43 in ALS was their co-
localization in neurons of ALS patients [100]. Analyses of
genome-wide RNA binding identified direct binding of
TDP-43 to RNA containing transposable elements (in-
cluding L1, Alu and ERV), and that this association was
reduced in patients with dysfunctional TDP-43 protein
aggregates [105]. A direct association was also shown with
the transfection of TDP-43 into human neurons leading
to the accumulation of HERVK transcripts and HERVK-
Env protein [101]. In a related study, over-expressing hu-
man TDP-43 in Drosophila neuron and glial cells resulted
in increased expression of multiple retrotransposons, with
the greatest effects on the gypsy viral-like LTR retrotrans-
poson [102]. Interestingly, overexpression of TDP-43 in
Drosophila glial cells caused greater retrotransposon
upregulation than in neuronal cells. Although TDP-43
overexpression in both cell types lead to motor dysfunc-
tion, the disease progression was more rapid in a glial ec-
topic expression model, with significant TDP-43
phosphorylation, cytoplasmic accumulation and cell death
[102]. However, other studies have shown that overexpres-
sion of TDP-43 alone was insufficient to increase HERVK
transcripts of fetal astrocytes or neuronal cultures in vitro,
and required proteasomal deficiencies and/or inflamma-
tory signals [106]. Intriguingly, both the overexpression
and depletion of TDP-43 in mouse models have been
shown to significantly upregulate transposable element ex-
pression, including that of ERVs [105]. Variant forms of
TDP-43 can self-aggregate into cytoplasmic inclusions in
neurons of ALS patients [107–109], and it is possible that
overexpression of TDP-43, rather than increasing the
functional protein level, might enhance self-aggregation
and further deplete TDP-43 in the nucleus. This is consist-
ent with experiments showing that N- or C-terminal
truncated TDP-43 (known to enhance aggregation [110])
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more strongly promote cytoplasmic aggregation of
HERVK proteins to stress granules in astrocytes [106].
However, this is in contrast with a study demonstrating
that knockdown of TDP-43 reduces HERVK expression
[101], as TDP-43 was shown to bind to the HERVK LTR
[101, 106] and enhance Pol-II association [101]. Add-
itional research is needed to determine if accumulation or
depletion of TDP-43 (or both) mediates up-regulation of
HERVK and other retrotransposons. As for other retro-
transposons, at least one study has shown that depletion
of nuclear TDP-43 is associated with increased L1HS ac-
cumulation in ALS post-mortem tissue, and that loss of
functional TDP-43 from human cells led to an increase in
L1HS retrotransposition activity [111].
TDP-43 may not be the only link between ALS disease
and retrotransposon expression. Several studies have
suggested a correlation between increased retrotrans-
poson expression levels and hexanucleotide (GGGGCC)
repeat expansion mutations in the non-coding region of
C9orf72 [112–114]. C9orf72 is the most commonly mu-
tated gene in familial forms of ALS, as well as a subset
of sporadic ALS disease [113–117]. Transcriptome pro-
filing studies showed that transposable element expres-
sion correlated more strongly with the presence C9orf72
repeat expansion in ALS patients, as compared to TDP-
43 transcript level or phosphorylated TDP-43 protein
levels [112, 115–117]. In these studies, the link between
C9orf72 and retrotransposon expression was indirect,
with evidence showing that C9orf72 peptides displaced
one of the major heterochromatin proteins (HP1),
resulting in a relaxation of heterochromatin structures
and accumulation of dsRNAs from heterochromatic ret-
rotransposons [112, 114].
In contrast to the multiple studies showing increased
TE and ERV products in ALS patients tissues and ani-
mal models of disease, three recent studies have failed to
find elevated levels of HERVK transcripts in ALS patient
tissues [113, 114, 118, 119]. Two studies argue that
HERVK transcripts show no difference between ALS pa-
tients and unaffected individuals [113, 118, 119], one
found no detectable HERVK-Env protein in cortex and
spinal cord by Western analysis [118, 119], while the
third found no evidence for general retrotransposon ele-
vation after reanalyzing published datasets [113, 118].
This may be due to differences in methodology, but
could also suggest heterogeneity in retrotransposon
levels among ALS patients. As to prevalence in ALS
populations, recent reviews summarizing the function of
ALS-associated genes has led to a growing appreciation
that ALS may be a molecularly heterogeneous disease,
with multiple parallel pathways leading towards a similar
phenotypic and clinical outcome [94, 113]. This could
explain the conflicting observations in ALS patient sam-
ples regarding HERVK expression and its correlation
with TDP-43 expression or pathology in smaller subsets
of sporadic patients. In contrast, patients carrying
C9orf72 mutations might represent a more similar pa-
tient group and show more consistency in terms of mo-
lecular pathways altered. It is therefore highly probable
that ALS patients represent a mixture of distinct mo-
lecular subtypes that show distinguishable differences in
retrotransposon expression and/or alterations in mul-
tiple molecular pathways. Thus, it is important to
characterize large ALS cohorts to definitively establish
the potential role and impact of retrotransposon activity
in the etiology of the disease.
Evidence for heterochromatin relaxation in
Alzheimer’s disease
Alzheimer’s disease (AD, OMIM 104300) is a neurode-
generative disorder that is marked by progressive dam-
age and loss of neurons in the central nervous system. It
is characterized pathologically by an accumulation of
intracellular neurofibrillary tangles of Tau protein and
extracellular amyloid plaques in the affected brain re-
gions. Patients most commonly present with memory
and language issues, later exhibiting decline in general
cognitive function and control of body functions, ultim-
ately leading to death [94, 120]. Genetic association
studies over the years have implicated more than 20 risk
alleles for dysfunctional amyloid processing, lipid metab-
olism, immune response, and general synaptic function
[120, 121]. However, these genes do not explain all of
the estimated heritability of AD, and disease onset is
likely to involve a complex interplay between genetic
and environmental factors [121, 122].
The role of retrotransposons in Alzheimer’s disease is
not well defined, but there is evidence that the epigenetic
landscape induced by Tau pathology could allow for
general transposon re-activation. Specifically, retrotran-
sposons have the highest density among the heterochro-
matic regions that are normally transcriptionally silent.
Overexpression of Tau in Drosophila shows significant
loss of heterochromatin across the genome, upregulation
of Ago3 (the Drosophila homolog of PIWIL1), and signifi-
cant locomotor dysfunction. The brains of Alzheimer’s
patients similarly show diffuse H3K9 di-methylation and
altered distributions of the major heterochromatin protein
HP1 in pyramidal neurons positive for disease-associated
Tau, as well as upregulation of PIWIL1 [122, 123].
Overexpression of Tau in aging Drosophila brains also
increased expression of certain retrotransposons [123,
124], and knockdown of a heterochromatin-associated
gene, BPTF, enhanced the locomotor dysfunction of the
transgenic Tau-overexpressing Drosophila, while knockout
of the ASH1L histone lysine methyltransferase (eu-
chromatin-associated) attenuated the phenotype [123,
124]. This suggests that the pervasive euchromatin state
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induced by Tau overexpression could be modified through
targeting of epigenetic regulators, and might be a possible
avenue for treatment.
In addition to chromatin changes, analysis of Alzhei-
mer’s brain samples also revealed gene expression profiles
that resemble fetal brain, with expression of several pluri-
potency-associated factors [123]. This suggests the possi-
bility for increased L1 retrotransposition, which has
previously been reported in neural progenitor cells of fetal
brains [11, 123, 125], especially given the observation that
retrotransposon expression shows positive association
with Tau pathology [11, 124, 125]. While there are some
indications of novel retrotransposition events in Alzhei-
mer’s patients [124, 126] and Drosophila models of Tau
pathology [124, 126], their extent and contribution to
pathology remains unresolved. Along with observations of
higher L1 methylation [124, 127] and no detectable
differences in the number of “active” L1 copies [126, 127]
in Alzheimer’s patients compared to unaffected individ-
uals, there are still open questions as to whether L1HS
specifically (among all retrotransposons) plays a role in
the etiology of Alzheimer’s disease.
Endogenous retrovirus levels have been shown to
positively correlate with Tau pathology in postmortem
dorsolateral prefrontal cortex of individuals from the
Religious Orders Study and Rush Memory and Aging
Project (ROSMAP) project [124, 126]. Overexpression of
Tau in aging Drosophila brain caused an increase in
LTR-class retrotransposons, while Alzheimer’s patients
with severe neurofibrillary tangles show enrichment of
H3K9 acetylation marks around HERV-Fc1 loci [124].
Yet, there have been no reports of increased reverse
transcriptase activity or presence of envelope proteins in
Alzheimer’s patients or animal models thus far.
Mutations and duplications of amyloid beta precursor
protein (APP) gene have been implicated in familial Alzhei-
mer’s disease [124, 128–130], while brains of sporadic Alz-
heimer’s patients show increased mosaic APP copy number
variation compared to healthy individuals [128–131]. A re-
cent study detected novel genomic copies of APP enriched
in neurons of sporadic Alzheimer’s patients that are remin-
iscent of processed/retroposed pseudogenes [131, 132].
These novel APP copies lack intronic sequence, and often
contain intra-exonic junctions (partial exon fusion) that ab-
late central exons of the APP gene. Ectopic expression of
human full-length APP in mouse brains show that the gen-
eration of novel APP genomic copies is transcription-
dependent [132]. While the study suggests that APP could
be undergoing somatic retro-insertion (which can be medi-
ated by retrotransposons such as L1), it remains unclear if
these novel APP variants have a pathogenic role in Alzhei-
mer’s disease, or if they are a by-product of other under-
lying pathogenic mechanisms. While these novel APP
variants are enriched in neurons of Alzheimer’s patients, it
is unclear if this is due to a chronic/ongoing elevation of
retrotransposition activity in these patients (of which there
is no evidence thus far), or from an elevated spike of retro-
insertion at an unspecified point during the patients’ life.
Additional studies are required to address these questions.
Finally, there exists within the genome several host
genes derived from endogenous retrotransposon se-
quences that might provide a more distant link between
TEs/ERVs and neurodegenerative disease. ARC is a neur-
onal gene involved in trafficking of glutamate receptors at
the synapse [132–135]. It associates with PSEN1 and me-
diates the internalization of APP from post mitotic
dendrites [133–136]. The ARC protein sequence has high
homology to retroviral Gag proteins [136, 137], and has
been shown to assemble into a viral-like capsid that
encapsulates RNA for intercellular transport [137–139].
ARC has been previously implicated in Alzheimer’s
disease as an enhancer of A-beta production, with
increased ARC protein in the medial frontal cortex of
Alzheimer’s patients. Arc enhances the association of
gamma secretase with APP in the endosome, and Alzhei-
mer’s mouse models lacking Arc show reduced plaque
and A-beta levels compared to those with functional Arc
[136, 138, 139]. However, an intriguing observation in
Drosophila found that Arc capsids could occasionally
encapsulate endogenous retroviral RNA [136, 138]. This
raises an interesting prospect that ARC could mediate the
spread of endogenous retroviral sequences between neu-
rons in neurodegenerative disorders (e.g. from cells with
elevated HERV expression). As such, Arc would likely
provide a transport system to allow for the spread of ERV
RNAs between cells, rather than a factor that induces ele-
vated expression of ERVs.
Conclusions
In summary, there is ample evidence for elevation of
certain retrotransposon RNAs and protein products in
postmortem patient tissues for multiple neurodegenera-
tive diseases and increased RT in patient biofluids. Specific
HERV Envelope proteins appear particularly neurotoxic.
However, questions remain regarding 1) which particular
retrotransposon products are elevated in each disease and
tissue context, 2) whether these elevated levels are ex-
pected to be present in all patients with the disease or in
subsets of patients, and 3) whether this elevated expres-
sion is just a marker of cellular dysfunction in each disease
or is pathogenic. Studies in Aicardi Goutieres Syndrome
(AGS) showed the best evidence to date for elevated retro-
transposon transcripts being present in patient tissues and
causing neuroinflammation through aberrant activation of
innate immune complexes. In AGS, patients carried
genetic mutations in complexes that normally process en-
dogenous retroelements, providing a mechanistic explan-
ation for elevated retrotransposon levels. Studies in ALS
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and MS have predominantly focused on the potential
neurotoxicity of HERV Envelope proteins from HERVK
and HERVW, respectively, though inflammatory
responses to transcripts could also play a role, especially
given the induction of inflammatory pathways seen in
both diseases. Finally, studies in Alzheimer’s disease
suggest an indirect elevation of retrotransposon levels
through heterochromatin relaxation induced by Tau path-
ology. Chromatin relaxation is thought to cause a wide-
spread depletion of heterochromatin associated proteins
from normally closed genomic regions with a consequent
opening of heterochromatin and increase of passive tran-
scription from these regions. This process has similarly
been hypothesized as a mechanism for inducing retro-
transposon expression in the subset of ALS patients carry-
ing C9orf72 mutations [114, 138]. Studies focused on
normally aging tissues from rodent models have shown
that retrotransposon de-silencing may happen as a conse-
quence of normal age-related alterations in chromatin
state [27, 28, 114, 140, 141], and that inflammatory path-
ways are induced downstream of retrotransposon activa-
tion. These studies suggest that elevated basal
retrotransposon levels may be a general feature of aging
that makes retrotransposon induced stress more likely in
aging-related neurodegenerative diseases.
One aging-related neurodegenerative disorder not dis-
cussed above, but potentially related, affects neurons in the
frontal and temporal lobes, Frontotemporal Dementia
(FTD). Specifically, a subset of ALS patients also develop
cognitive issues or behavioral changes that are understood
to result from FTD, an umbrella term for a group of clinical
dementia syndromes that correlate with the pathologic
finding of Frontotemporal Lobar Degeneration (FTLD)
(OMIM 600274). The ALS-Frontotemporal Spectrum Dis-
order is more common in patients with familial forms of
ALS. Mutations in the C9orf72 gene are the most common
cause of hereditary FTD, ALS, and ALS with FTD. Several
other genes are now recognized to cause both diseases.
This has led to speculation that the familial forms of ALS
and some forms of FTLD might be related genetic diseases
that predominantly differ in terms of the affected tissues at
onset, but may share molecular mechanisms of pathogen-
esis [27, 28, 140–145]. FTD and its spectrum disorders
were not included above due to a current lack of direct evi-
dence linking TEs to FTD in patient tissues, though any
discussion of TE expression downstream of TDP-43 and
C9orf72 induced pathology could apply to some FTD-
spectrum disorders as well.
None of these studies have yet shown clear evidence
for de novo insertions, or “hopping,” of the retrotranspo-
sons in decedent patient tissues or laboratory models,
though it is possible that improved methods for identify-
ing somatic de novo insertions may shed more light on
this possibility. As sequencing technologies improve with
longer reads [142–147], better protocols for transposon
insertion profiling [146–151], and better computational
tools to handle repetitive genomic regions [148–152], it
may be easier to detect retrotransposon products ran-
ging from specific loci generating elevated retrotrans-
poson transcripts to polymorphic and de novo genome
insertions.
Abbreviations
A to I: Adenosine to inosine; AD: Alzheimer’s disease; AGS: Aicardi-Goutieres
syndrome; ALS: Amyotrophic lateral sclerosis; ALSFRS-R: Amyotrophic lateral
sclerosis functional rating scale - revised; cDNA: Complementary
deoxyribonucleic acids; CIDP: Chronic Inflammatory Demyelinating
Polyradiculoneuropathy; CNS: Central nervous system; CSF: Cerebrospinal
fluid; DNA: Deoxyribonucleic acids; dNTP: Deoxyribonucleoside Tri-
phosphate; dsRNA: Double-stranded Ribonucleic acids; ELISA: Enzyme-linked
immunosorbent assay; ERV: Endogenous retrovirus; FTD: Frontotemporal
dementia; FTLD: Frontotemporal lobar degeneration; GTF: Guanosine Tri-
phosphate; H3K9: Histone 3, Lysine 9; HD domain: Histidine/Aspartate-rich
domain; HEK293T: Human embryonic kidney 293 cells with SV40 large T
antigen; HERV: Human(−specific) endogenous retrovirus;
HERVH: Human(−specific) endogenous retrovirus, group H;
HERVK: Human(−specific) endogenous retrovirus, group K; HERVK-
Env: Human(−specific) endogenous retrovirus, group K, envelope; HERVK-
RT: Human(−specific) endogenous retrovirus, group K, reverse transcriptase;
HERVW: Human(−specific) endogenous retrovirus, group W; HERVW-
Env: Human(−specific) endogenous retrovirus, group W, envelope; L1: Long
interspersed nuclear element 1; L1HS: Long interspersed nuclear element 1,
Homo sapiens; LINE: Long interspersed nuclear element; LTR: Long terminal
repeat; MHC: Major histocompatibility complex; MS: Multiple sclerosis;
PBMC: Peripheral blood mononuclear cells; qPCR: Quantitative polymerase
chain reaction; RNA: Ribonucleic acids; ROSMAP: Religious Orders Study and
Rush Memory and Aging Project; RT: Reverse transcriptase; RTI: Reverse
transcriptase inhibitor; RT-PCR: Reverse transcription and polymerase chain
reaction; sALS: Sporadic amyotrophic lateral sclerosis; SAM: Sterile alpha
motif; SINE: Short interspersed nuclear element; siRNA: Short interfering
ribonucleic acids; SVA: SINE/VNTR/Alu elements; TE: Transposable elements;
UTR: Untranslated Region
Acknowledgements
We thank members of the Gale-Hammell lab for helpful discussions and
comments. Schematic images were adapted with permission from Servier
Medical Art (https://smart.servier.com).
Authors’ contributions
All authors (OT, LWO, MGH) wrote, read, and approved the final manuscript.
Funding
MGH is funded by the Rita Allen Foundation. LWO is funded by The Target
ALS Foundation and the ALS Association. MGH and OT are funded by the
Chan Zuckerberg Initiative as part of the Neurodegeneration Challenge
Network.
Availability of data and materials
Not applicable.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Quantitative Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
11724, USA. 2Department of Neurology, Johns Hopkins University School of
Medicine, Baltimore, MD 21205, USA.
Tam et al. Mobile DNA           (2019) 10:32 Page 10 of 14
Received: 9 May 2019 Accepted: 18 July 2019
References
1. Goodier JL, Kazazian HH. Retrotransposons revisited: the restraint and
rehabilitation of parasites. Cell. 2008;135(1):23–35.
2. Levin HL, Moran JV. Dynamic interactions between transposable elements
and their hosts. Nat Rev Genet. 2011;12(9):615–27.
3. Bourque G, Burns KH, Gehring M, Gorbunova V, Seluanov A, Hammell M,
et al. Ten things you should know about transposable elements. Genome
Biol. 2018;19(1):199.
4. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial
sequencing and analysis of the human genome. Nature. 2001;409(6822):860–921.
5. Johnson WE. Origins and evolutionary consequences of ancient
endogenous retroviruses. Nat Rev Microbiol. 2019;17(6):355–79.
6. Brouha B, Schustak J, Badge RM, Lutz-Prigge S, Farley AH, Moran JV, et al.
Hot L1s account for the bulk of retrotransposition in the human population.
Proc Natl Acad Sci U S A. 2003;100(9):5280–5.
7. Beck CR, Collier P, Macfarlane C, Malig M, Kidd JM, Eichler EE, et al. LINE-1
retrotransposition activity in human genomes. Cell. 2010;141(7):1159–70.
8. Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M, et al. Mobile DNA
in cancer. Extensive transduction of nonrepetitive DNA mediated by L1
retrotransposition in cancer genomes. Science. 2014;345(6196):1251343.
9. Philippe C, Vargas-Landin DB, Doucet AJ, van Essen D, Vera-Otarola J, Kuciak
M, et al. Activation of individual L1 retrotransposon instances is restricted to
cell-type dependent permissive loci. Elife. 2016;5. https://doi.org/10.7554/
eLife.13926.
10. Stewart C, Kural D, Strömberg MP, Walker JA, Konkel MK, Stütz AM, et al. A
comprehensive map of mobile element insertion polymorphisms in
humans. PLoS Genet. 2011;7(8):e1002236.
11. Muotri AR, Chu VT, Marchetto MCN, Deng W, Moran JV, Gage FH. Somatic
mosaicism in neuronal precursor cells mediated by L1 retrotransposition.
Nature. 2005;435(7044):903–10.
12. Upton KR, Gerhardt DJ, Jesuadian JS, Richardson SR, Sánchez-Luque FJ,
Bodea GO, et al. Ubiquitous l1 mosaicism in hippocampal neurons. Cell.
2015;161(2):228–39.
13. Erwin JA, Paquola ACM, Singer T, Gallina I, Novotny M, Quayle C, et al. L1-
associated genomic regions are deleted in somatic cells of the healthy
human brain. Nat Neurosci. 2016;19(12):1583–91.
14. Evrony GD, Lee E, Park PJ, Walsh CA. Resolving rates of mutation in the
brain using single-neuron genomics. Elife. 2016;5.
15. Hazen JL, Faust GG, Rodriguez AR, Ferguson WC, Shumilina S, Clark RA, et al.
The complete genome sequences, unique mutational spectra, and
developmental potency of adult neurons revealed by cloning. Neuron.
2016;89(6):1223–36.
16. Bodea GO, McKelvey EGZ, Faulkner GJ. Retrotransposon-induced mosaicism
in the neural genome. Open Biol. 2018;8(7).
17. Jacob-Hirsch J, Eyal E, Knisbacher BA, Roth J, Cesarkas K, Dor C, et al. Whole-
genome sequencing reveals principles of brain retrotransposition in
neurodevelopmental disorders. Cell Res. 2018;28(2):187–203.
18. Burns KH. Transposable elements in cancer. Nat Rev Cancer. 2017;17(7):415–24.
19. Tang Z, Steranka JP, Ma S, Grivainis M, Rodić N, Huang CRL, et al.
Human transposon insertion profiling: analysis, visualization and
identification of somatic LINE-1 insertions in ovarian cancer. Proc Natl
Acad Sci. 2017;114(5):E733–40.
20. Jung H, Choi JK, Lee EA. Immune signatures correlate with L1
retrotransposition in gastrointestinal cancers. Genome Res. 2018;28(8):1136–46.
21. Nigumann P, Redik K, Mätlik K, Speek M. Many human genes are transcribed
from the antisense promoter of L1 retrotransposon. Genomics. 2002;79(5):628–34.
22. Cohen CJ, Lock WM, Mager DL. Endogenous retroviral LTRs as promoters for
human genes: a critical assessment. Gene. 2009;448(2):105–14.
23. ENCODE Project Consortium. An integrated encyclopedia of DNA elements
in the human genome. Nature. 2012;489(7414):57–74.
24. Kassiotis G, Stoye JP. Immune responses to endogenous retroelements:
taking the bad with the good. Nat Rev Immunol. 2016;16(4):207–19.
25. Bazak L, Haviv A, Barak M, Jacob-Hirsch J, Deng P, Zhang R, et al. A-to-I RNA
editing occurs at over a hundred million genomic sites, located in a
majority of human genes. Genome Res. 2014;24(3):365–76.
26. Solomon O, Di Segni A, Cesarkas K, Porath HT, Marcu-Malina V, Mizrahi O, et
al. RNA editing by ADAR1 leads to context-dependent transcriptome-wide
changes in RNA secondary structure. Nat Commun. 2017;8(1):1440.
27. De Cecco M, Ito T, Petrashen AP, Elias AE, Skvir NJ, Criscione SW, et al. L1
drives IFN in senescent cells and promotes age-associated inflammation.
Nature. 2019;566(7742):73–8.
28. Simon M, Van Meter M, Ablaeva J, Ke Z, Gonzalez RS, Taguchi T, et al. LINE1
Derepression in aged wild-type and SIRT6-deficient mice drives
inflammation. Cell Metab. 2019;29(4):871–5.
29. Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, et al.
Inhibiting DNA methylation causes an interferon response in cancer via
dsRNA including endogenous retroviruses. Cell. 2015;162(5):974–86.
30. Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, et al. DNA-
Demethylating agents target colorectal cancer cells by inducing viral
mimicry by endogenous transcripts. Cell. 2015;162(5):961–73.
31. Antony JM, van Marle G, Opii W, Butterfield DA, Mallet F, Yong VW, et al.
Human endogenous retrovirus glycoprotein-mediated induction of redox
reactants causes oligodendrocyte death and demyelination. Nat Neurosci.
2004;7(10):1088–95.
32. Douville RN, Nath A. Human endogenous retrovirus-K and TDP-43 expression
bridges ALS and HIV neuropathology. Front Microbiol. 2017;8:1986.
33. Aicardi J, Goutières F. A progressive familial encephalopathy in infancy with
calcifications of the basal ganglia and chronic cerebrospinal fluid
lymphocytosis. Ann Neurol. 1984;15(1):49–54.
34. Stephenson JBP. Aicardi-Goutières syndrome (AGS). Eur J Paediatr Neurol.
2008;12(5):355–8.
35. Crow YJ, Hayward BE, Parmar R, Robins P, Leitch A, Ali M, et al. Mutations in
the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-
Goutières syndrome at the AGS1 locus. Nat Genet. 2006;38(8):917–20.
36. Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW, Carr IM, et al. Mutations
involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of
the innate immune response. Nat Genet. 2009;41(7):829–32.
37. Rice GI, Kasher PR, Forte GMA, Mannion NM, Greenwood SM, Szynkiewicz
M, et al. Mutations in ADAR1 cause Aicardi-Goutières syndrome associated
with a type I interferon signature. Nat Genet. 2012;44(11):1243–8.
38. Rice GI, del Toro DY, Jenkinson EM, Forte GM, Anderson BH, Ariaudo G,
et al. Gain-of-function mutations in IFIH1 cause a spectrum of human
disease phenotypes associated with upregulated type I interferon signaling.
Nat Genet. 2014;46(5):503–9.
39. Crow YJ, Leitch A, Hayward BE, Garner A, Parmar R, Griffith E, et al.
Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-
Goutières syndrome and mimic congenital viral brain infection. Nat Genet.
2006;38(8):910–6.
40. Rice GI, Forte GMA, Szynkiewicz M, Chase DS, Aeby A, Abdel-Hamid MS,
et al. Assessment of interferon-related biomarkers in Aicardi-Goutières
syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B,
RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol. 2013;
12(12):1159–69.
41. Crow YJ, Manel N. Aicardi-Goutières syndrome and the type I
interferonopathies. Nat Rev Immunol. 2015;15(7):429–40.
42. Li P, Du J, Goodier JL, Hou J, Kang J, Kazazian HH Jr, et al. Aicardi–Goutières
syndrome protein TREX1 suppresses L1 and maintains genome integrity through
exonuclease-independent ORF1p depletion. Nucleic Acids Res. 2017;45(8):4619–31.
43. Thomas CA, Tejwani L, Trujillo CA, Negraes PD, Herai RH, Mesci P, et al.
Modeling of TREX1-dependent autoimmune disease using human stem
cells highlights L1 accumulation as a source of neuroinflammation. Cell
Stem Cell. 2017;21(3):319–331.e8.
44. Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic
initiation of autoimmunity. Cell. 2008;134(4):587–98.
45. Zhao K, Du J, Han X, Goodier JL, Li P, Zhou X, et al. Modulation of LINE-1
and Alu/SVA retrotransposition by Aicardi-Goutières syndrome-related
SAMHD1. Cell Rep. 2013;4(6):1108–15.
46. Hu S, Li J, Xu F, Mei S, Le Duff Y, Yin L, et al. SAMHD1 inhibits LINE-1
retrotransposition by promoting stress granule formation. PLoS Genet. 2015;
11(7):e1005367.
47. Herrmann A, Wittmann S, Thomas D, Shepard CN, Kim B, Ferreirós N, et al.
The SAMHD1-mediated block of LINE-1 retroelements is regulated by
phosphorylation. Mob DNA. 2018;9:11.
48. Du J, Peng Y, Wang S, Hou J, Wang Y, Sun T, et al. Nucleocytoplasmic
shuttling of SAMHD1 is important for LINE-1 suppression. Biochem Biophys
Res Commun. 2019;510(4):551–7.
49. Orecchini E, Doria M, Antonioni A, Galardi S, Ciafrè SA, Frassinelli L,
et al. ADAR1 restricts LINE-1 retrotransposition. Nucleic Acids Res. 2017;
45(1):155–68.
Tam et al. Mobile DNA           (2019) 10:32 Page 11 of 14
50. Chung H, Calis JJA, Wu X, Sun T, Yu Y, Sarbanes SL, et al. Human ADAR1
prevents endogenous RNA from triggering translational shutdown. Cell.
2018;172(4):811–4.
51. Ahmad S, Mu X, Yang F, Greenwald E, Park JW, Jacob E, et al. Breaching
Self-Tolerance to Alu Duplex RNA Underlies MDA5-Mediated Inflammation.
Cell. 2018;172(4):797–810.e13.
52. Mannion NM, Greenwood SM, Young R, Cox S, Brindle J, Read D, et al. The
RNA-editing enzyme ADAR1 controls innate immune responses to RNA. Cell
Rep. 2014;9(4):1482–94.
53. Liddicoat BJ, Piskol R, Chalk AM, Ramaswami G, Higuchi M, Hartner JC, et al.
RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as
nonself. Science. 2015;349(6252):1115–20.
54. Pestal K, Funk CC, Snyder JM, Price ND, Treuting PM, Stetson DB. Isoforms of
RNA-editing enzyme ADAR1 independently control nucleic acid sensor
MDA5-driven autoimmunity and multi-organ development. Immunity. 2015;
43(5):933–44.
55. George CX, Ramaswami G, Li JB, Samuel CE. Editing of cellular self-RNAs by
adenosine deaminase ADAR1 suppresses innate immune stress responses. J
Biol Chem. 2016;291(12):6158–68.
56. Beck-Engeser GB, Eilat D, Wabl M. An autoimmune disease prevented by
anti-retroviral drugs. Retrovirology. 2011;8:91.
57. Achleitner M, Kleefisch M, Hennig A, Peschke K, Polikarpova A, Oertel R,
et al. Lack of Trex1 causes systemic autoimmunity despite the presence of
antiretroviral drugs. J Immunol. 2017;199(7):2261–9.
58. Rice GI, Meyzer C, Bouazza N, Hully M, Boddaert N, Semeraro M, et al.
Reverse-transcriptase inhibitors in the Aicardi–Goutières syndrome. N Engl J
Med. 2018;379(23):2275–7.
59. Bartsch K, Knittler K, Borowski C, Rudnik S, Damme M, Aden K, et al.
Absence of RNase H2 triggers generation of immunogenic micronuclei
removed by autophagy. Hum Mol Genet. 2017;26(20):3960–72.
60. Mackenzie KJ, Carroll P, Martin C-A, Murina O, Fluteau A, Simpson DJ, et al.
cGAS surveillance of micronuclei links genome instability to innate
immunity. Nature. 2017;548(7668):461–5.
61. Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple
sclerosis. Nat Rev Dis Primers. 2018;4(1):43.
62. Baranzini SE, Oksenberg JR. The genetics of multiple sclerosis: from 0 to 200
in 50 years. Trends Genet. 2017;33(12):960–70.
63. Perron H, Geny C, Laurent A, Mouriquand C, Pellat J, Perret J, et al.
Leptomeningeal cell line from multiple sclerosis with reverse transcriptase
activity and viral particles. Res Virol. 1989;140(6):551–61.
64. Perron H, Garson JA, Bedin F, Beseme F, Paranhos-Baccala G, Komurian-
Pradel F, et al. Molecular identification of a novel retrovirus repeatedly
isolated from patients with multiple sclerosis. The collaborative research
group on multiple sclerosis. Proc Natl Acad Sci U S A. 1997;94(14):7583–8.
65. Sotgiu S, Mameli G, Serra C, Zarbo IR, Arru G, Dolei A. Multiple sclerosis-
associated retrovirus and progressive disability of multiple sclerosis. Mult
Scler. 2010;16(10):1248–51.
66. Garson JA, Tuke PW, Giraud P, Paranhos-Baccala G, Perron H. Detection of
virion-associated MSRV-RNA in serum of patients with multiple sclerosis.
Lancet. 1998;351(9095):33.
67. Perron H, Germi R, Bernard C, Garcia-Montojo M, Deluen C, Farinelli L, et al.
Human endogenous retrovirus type W envelope expression in blood and
brain cells provides new insights into multiple sclerosis disease. Mult Scler.
2012;18(12):1721–36.
68. Komurian-Pradel F, Paranhos-Baccala G, Bedin F, Ounanian-Paraz A, Sodoyer
M, Ott C, et al. Molecular cloning and characterization of MSRV-related
sequences associated with retrovirus-like particles. Virology. 1999;260(1):1–9.
69. Perron H, Lazarini F, Ruprecht K, Péchoux-Longin C, Seilhean D, Sazdovitch
V, et al. Human endogenous retrovirus (HERV)-W ENV and GAG proteins:
physiological expression in human brain and pathophysiological
modulation in multiple sclerosis lesions. J Neuro-Oncol. 2005;11(1):23–33.
70. van Horssen J, van der Pol S, Nijland P, Amor S, Perron H. Human
endogenous retrovirus W in brain lesions: rationale for targeted therapy in
multiple sclerosis. Mult Scler Relat Disord. 2016;8:11–8.
71. Madeira A, Burgelin I, Perron H, Curtin F, Lang AB, Faucard R. MSRV
envelope protein is a potent, endogenous and pathogenic agonist of
human toll-like receptor 4: relevance of GNbAC1 in multiple sclerosis
treatment. J Neuroimmunol. 2016;291:29–38.
72. Antony JM, Ellestad KK, Hammond R, Imaizumi K, Mallet F, Warren KG, et al.
The human endogenous retrovirus envelope glycoprotein, Syncytin-1,
regulates Neuroinflammation and its receptor expression in multiple
sclerosis: A role for endoplasmic reticulum chaperones in astrocytes. J
Immunol. 2007;179(2):1210–24.
73. Mameli G, Astone V, Arru G, Marconi S, Lovato L, Serra C, et al. Brains and
peripheral blood mononuclear cells of multiple sclerosis (MS) patients
hyperexpress MS-associated retrovirus/HERV-W endogenous retrovirus, but
not human herpesvirus 6. J Gen Virol. 2007;88(Pt 1):264–74.
74. Brudek T, Christensen T, Aagaard L, Petersen T, Hansen HJ, Møller-Larsen A.
B cells and monocytes from patients with active multiple sclerosis exhibit
increased surface expression of both HERV-H Env and HERV-W Env,
accompanied by increased seroreactivity. Retrovirology. 2009;6(1):A40.
75. Arru G, Mameli G, Deiana GA, Rassu AL, Piredda R, Sechi E, et al. Humoral
immunity response to human endogenous retroviruses K/W differentiates
between amyotrophic lateral sclerosis and other neurological diseases. Eur J
Neurol. 2018;25(8):1076–84.
76. Garcia-Montojo M, de la Hera B, Varadé J, de la Encarnación A, Camacho I,
Domínguez-Mozo M, et al. HERV-W polymorphism in chromosome X is
associated with multiple sclerosis risk and with differential expression of
MSRV. Retrovirology. 2014;11:2.
77. Laufer G, Mayer J, Mueller BF, Mueller-Lantzsch N, Ruprecht K. Analysis of
transcribed human endogenous retrovirus W env loci clarifies the origin of
multiple sclerosis-associated retrovirus env sequences. Retrovirology. 2009;6:37.
78. Schmitt K, Richter C, Backes C, Meese E, Ruprecht K, Mayer J.
Comprehensive analysis of human endogenous retrovirus group HERV-W
locus transcription in multiple sclerosis brain lesions by high-throughput
amplicon sequencing. J Virol. 2013;87(24):13837–52.
79. Garson JA, Huggett JF, Bustin SA, Pfaffl MW, Benes V, Vandesompele J, et al.
Unreliable real-time PCR analysis of human endogenous retrovirus-W (HERV-
W) RNA expression and DNA copy number in multiple sclerosis. AIDS Res
Hum Retroviruses. 2009;25(3):377–8 authorreply379–81.
80. Mi S, Lee X, Li X, Veldman GM, Finnerty H, Racie L, et al. Syncytin is a
captive retroviral envelope protein involved in human placental
morphogenesis. Nature. 2000;403(6771):785–9.
81. Chen C-P, Chen L-F, Yang S-R, Chen C-Y, Ko C-C, Chang G-D, et al.
Functional characterization of the human placental fusogenic membrane
protein syncytin 2. Biol Reprod. 2008;79(5):815–23.
82. Roebke C, Wahl S, Laufer G, Stadelmann C, Sauter M, Mueller-Lantzsch N, et al. An
N-terminally truncated envelope protein encoded by a human endogenous
retrovirus W locus on chromosome Xq22.3. Retrovirology. 2010;7:69.
83. do Olival GS, Faria TS, LHS N, de Oliveira ACP, Casseb J, Vidal JE, et al.
Genomic analysis of ERVWE2 locus in patients with multiple sclerosis:
absence of genetic association but potential role of human endogenous
retrovirus type W elements in molecular mimicry with myelin antigen. Front
Microbiol. 2013;4:172.
84. Curtin F, Lang AB, Perron H, Laumonier M, Vidal V, Porchet HC, et al.
GNbAC1, a humanized monoclonal antibody against the envelope protein
of multiple sclerosis-associated endogenous retrovirus: a first-in-humans
randomized clinical study. Clin Ther. 2012;34(12):2268–78.
85. Zimmermann M, Sanderson NSR, Rasenack M, Lalive PH, Lang AB, Curtin F, et al.
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in
patients with MS. Neurol Neuroimmunol Neuroinflamm. 2015;2(5):e144.
86. Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, et al. A phase
IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody
against the envelope protein of multiple sclerosis-associated endogenous
retrovirus in multiple sclerosis patients. Mult Scler. 2015;21(7):885–93.
87. Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, et al. A
phase IIa randomized clinical study testing GNbAC1, a humanized
monoclonal antibody against the envelope protein of multiple sclerosis
associated endogenous retrovirus in multiple sclerosis patients - a twelve
month follow-up. J Neuroimmunol. 2015;285:68–70.
88. Diebold M, Derfuss T. The monoclonal antibody GNbAC1: targeting human
endogenous retroviruses in multiple sclerosis. Ther Adv Neurol Disord. 2019;
12:1756286419833574.
89. Faucard R, Madeira A, Gehin N, Authier F-J, Panaite P-A, Lesage C, et al. Human
endogenous retrovirus and Neuroinflammation in chronic inflammatory
demyelinating Polyradiculoneuropathy. EBioMedicine. 2016;6:190–8.
90. Nexø BA, Christensen T, Frederiksen J, Møller-Larsen A, Oturai AB, Villesen P, et al. The
etiology of multiple sclerosis: genetic evidence for the involvement of the human
endogenous retrovirus HERV-Fc1. Belshaw R, editor. PLoS One. 2011;6(2):e16652.
91. Laska MJ, Brudek T, Nissen KK, Christensen T, Moller-Larsen A, Petersen T,
et al. Expression of HERV-Fc1, a human endogenous retrovirus, is increased
in patients with active multiple sclerosis. J Virol. 2012;86(7):3713–22.
Tam et al. Mobile DNA           (2019) 10:32 Page 12 of 14
92. Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W,
et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.
93. Cook C, Petrucelli L. Genetic convergence brings clarity to the enigmatic
red line in ALS. Neuron. 2019;101(6):1057–69.
94. Taylor JP, Brown RH, Cleveland DW. Decoding ALS: from genes to
mechanism. Nature. 2016;539(7628):197–206.
95. Chen-Plotkin AS, Lee VM-Y, Trojanowski JQ. TAR DNA-binding protein 43 in
neurodegenerative disease. Nat Rev Neurol. 2010;6(4):211–20.
96. Andrews WD, Tuke PW, Al-Chalabi A, Gaudin P, Ijaz S, Parton MJ, et al.
Detection of reverse transcriptase activity in the serum of patients with
motor neurone disease. J Med Virol. 2000;61(4):527–32.
97. Steele AJ, Al-Chalabi A, Ferrante K, Cudkowicz ME, Brown RH, Garson JA.
Detection of serum reverse transcriptase activity in patients with ALS and
unaffected blood relatives. Neurology. 2005;64(3):454–8.
98. MacGowan DJL, Scelsa SN, Imperato TE, Liu K-N, Baron P, Polsky B. A
controlled study of reverse transcriptase in serum and CSF of HIV-negative
patients with ALS. Neurology. 2007;68(22):1944–6.
99. McCormick AL, Brown RH, Cudkowicz ME, Al-Chalabi A, Garson JA.
Quantification of reverse transcriptase in ALS and elimination of a novel
retroviral candidate. Neurology. 2008;70(4):278–83.
100. Douville R, Liu J, Rothstein J, Nath A. Identification of active loci of a human
endogenous retrovirus in neurons of patients with amyotrophic lateral
sclerosis. Ann Neurol. 2011;69(1):141–51.
101. Li W, Lee M-H, Henderson L, Tyagi R, Bachani M, Steiner J, et al. Human
endogenous retrovirus-K contributes to motor neuron disease. Sci Transl
Med. 2015;7(307):307ra153.
102. Krug L, Chatterjee N, Borges-Monroy R, Hearn S, Liao W-W, Morrill K, et al.
Retrotransposon activation contributes to neurodegeneration in a Drosophila
TDP-43 model of ALS. Feschotte C, editor. PLoS Genet. 2017;13(3):e1006635.
103. Manghera M, Ferguson-Parry J, Lin R, Douville RN. NF-κB and IRF1 induce
endogenous retrovirus K expression via interferon-stimulated response
elements in its 5′ long terminal repeat. J Virol. 2016;90(20):9338–49.
104. Ou SH, Wu F, Harrich D, García-Martínez LF, Gaynor RB. Cloning and
characterization of a novel cellular protein, TDP-43, that binds to human
immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol. 1995;
69(6):3584–96.
105. Li W, Jin Y, Prazak L, Hammell M, Dubnau J. Transposable elements in TDP-
43-mediated neurodegenerative disorders. PLoS One. 2012;7(9):e44099.
106. Manghera M, Ferguson-Parry J, Douville RN. TDP-43 regulates endogenous
retrovirus-K viral protein accumulation. Neurobiol Dis. 2016;94:226–36.
107. Mackenzie IRA, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, et al.
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from
amyotrophic lateral sclerosis withSOD1 mutations. Ann Neurol. 2007;61(5):427–34.
108. Yamashita T, Hideyama T, Hachiga K, Teramoto S, Takano J, Iwata N, et al. A
role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral
sclerosis pathology. Nat Commun. 2012;3:1307.
109. Yamashita T, Teramoto S, Kwak S. Phosphorylated TDP-43 becomes resistant
to cleavage by calpain: A regulatory role for phosphorylation in TDP-43
pathology of ALS/FTLD. Neurosci Res. 2016;107:63–9.
110. Yang C, Tan W, Whittle C, Qiu L, Cao L, Akbarian S, et al. The C-terminal
TDP-43 fragments have a high aggregation propensity and harm neurons
by a dominant-negative mechanism. PLoS One. 2010;5(12):e15878.
111. Liu EY, Russ J, Cali CP, Phan JM, Amlie-Wolf A, Lee EB. Loss of nuclear TDP-
43 is associated with decondensation of LINE retrotransposons. Cell Rep.
2019;27(5):1409–1421.e6.
112. Prudencio M, Gonzales PK, Cook CN, Gendron TF, Daughrity LM, Song Y,
et al. Repetitive element transcripts are elevated in the brain of C9orf72
ALS/FTLD patients. Hum Mol Genet. 2017;26(17):3421–31.
113. Pereira GC, Sanchez L, Schaughency PM, Rubio-Roldán A, Choi JA, Planet E,
et al. Properties of LINE-1 proteins and repeat element expression in the
context of amyotrophic lateral sclerosis. Mob DNA. 2018;9:35.
114. Zhang Y-J, Guo L, Gonzales PK, Gendron TF, Wu Y, Jansen-West K, et al.
Heterochromatin anomalies and double-stranded RNA accumulation
underlie C9orf72 poly(PR) toxicity. Science. 2019;15, 363(6428).
115. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M,
Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in
noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.
Neuron. 2011;72(2):245–56.
116. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR,
et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of
chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257–68.
117. Conlon EG, Fagegaltier D, Agius P, Davis-Porada J, Gregory J, Hubbard I,
et al. Unexpected similarities between C9ORF72 and sporadic forms of ALS/
FTD suggest a common disease mechanism. Elife. 2018;7.
118. Mayer J, Harz C, Sanchez L, Pereira GC, Maldener E, Heras SR, et al.
Transcriptional profiling of HERV-K(HML-2) in amyotrophic lateral sclerosis
and potential implications for expression of HML-2 proteins. Mol
Neurodegener. 2018;13(1):39.
119. Garson JA, Usher L, Al-Chalabi A, Huggett J, Day EF, McCormick AL.
Quantitative analysis of human endogenous retrovirus-K transcripts in
postmortem premotor cortex fails to confirm elevated expression of HERV-K
RNA in amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2019;7(1):45.
120. Alzheimer’s Association. 2016 Alzheimer’s disease facts and figures.
Alzheimers Dement. 2016;12(4):459–509.
121. Karch CM, Cruchaga C, Goate AM. Alzheimer’s disease genetics: from the
bench to the clinic. Neuron. 2014;83(1):11–26.
122. Ridge PG, Mukherjee S, Crane PK, JSK K, Alzheimer’s Disease Genetics
Consortium. Alzheimer's disease: analyzing the missing heritability. PLoS
One. 2013;8(11):e79771.
123. Frost B, Hemberg M, Lewis J, Feany MB. Tau promotes neurodegeneration
through global chromatin relaxation. Nat Neurosci. 2014;17(3):357–66.
124. Guo C, Jeong H-H, Hsieh Y-C, Klein H-U, Bennett DA, De Jager PL, et al. Tau activates
transposable elements in Alzheimer's disease. Cell Rep. 2018;23(10):2874–80.
125. Coufal NG, García-Pérez JL, Peng GE, Yeo GW, Mu Y, Lovci MT, et al. L1
retrotransposition in human neural progenitor cells. Nature. 2009;
460(7259):1127–31.
126. Protasova MS, Gusev FE, Grigorenko AP, Kuznetsova IL, Rogaev EI, Andreeva
TV. Quantitative analysis of L1-retrotransposons in Alzheimer's disease and
aging. Biochemistry (Mosc). 2017;82(8):962–71.
127. Bollati V, Galimberti D, Pergoli L, Dalla Valle E, Barretta F, Cortini F, et al. DNA
methylation in repetitive elements and Alzheimer disease. Brain Behav
Immun. 2011;25(6):1078–83.
128. Murrell J, Farlow M, Ghetti B, Benson MD. A mutation in the amyloid
precursor protein associated with hereditary Alzheimer’s disease. Science.
1991;254(5028):97–9.
129. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, et al. A
pathogenic mutation for probable Alzheimer's disease in the APP gene at
the N-terminus of beta-amyloid. Nat Genet. 1992;1(5):345–7.
130. Hooli BV, Kovacs-Vajna ZM, Mullin K, Blumenthal MA, Mattheisen M, Zhang
C, et al. Rare autosomal copy number variations in early-onset familial
Alzheimer’s disease. Mol Psychiatry. 2014;19(6):676–81.
131. Bushman DM, Kaeser GE, Siddoway B, Westra JW, Rivera RR, Rehen SK, et al.
Genomic mosaicism with increased amyloid precursor protein (APP) gene
copy number in single neurons from sporadic Alzheimer's disease brains.
Elife. 2015;4.
132. Lee M-H, Siddoway B, Kaeser GE, Segota I, Rivera R, Romanow WJ, et al.
Somatic APP gene recombination in Alzheimer's disease and normal
neurons. Nature. 2018;563(7733):639–45.
133. Chowdhury S, Shepherd JD, Okuno H, Lyford G, Petralia RS, Plath N, et al.
Arc/Arg3.1 interacts with the endocytic machinery to regulate AMPA
receptor trafficking. Neuron. 2006;52(3):445–59.
134. Shepherd JD, Rumbaugh G, Wu J, Chowdhury S, Plath N, Kuhl D, et al. Arc/
Arg3.1 mediates homeostatic synaptic scaling of AMPA receptors. Neuron.
2006;52(3):475–84.
135. Park S, Park JM, Kim S, Kim J-A, Shepherd JD, Smith-Hicks CL, et al.
Elongation factor 2 and fragile X mental retardation protein control the
dynamic translation of arc/Arg3.1 essential for mGluR-LTD. Neuron. 2008;
59(1):70–83.
136. Wu J, Petralia RS, Kurushima H, Patel H, Jung M-Y, Volk L, et al. Arc/Arg3.1
regulates an endosomal pathway essential for activity-dependent β-amyloid
generation. Cell. 2011;147(3):615–28.
137. Campillos M, Doerks T, Shah PK, Bork P. Computational characterization of
multiple gag-like human proteins. Trends Genet. 2006;22(11):585–9.
138. Ashley J, Cordy B, Lucia D, Fradkin LG, Budnik V, Thomson T. Retrovirus-like
Gag Protein Arc1 Binds RNA and Traffics across Synaptic Boutons. Cell. 2018;
172(1–2):262–274.e11.
139. Pastuzyn ED, Day CE, Kearns RB, Kyrke-Smith M, Taibi AV, McCormick J, et al.
The neuronal gene arc encodes a repurposed retrotransposon Gag protein
that mediates intercellular RNA transfer. Cell. 2018;172(1–2):275–288.e18.
140. Van Meter M, Kashyap M, Rezazadeh S, Geneva AJ, Morello TD, Seluanov A,
et al. SIRT6 represses LINE1 retrotransposons by ribosylating KAP1 but this
repression fails with stress and age. Nat Commun. 2014;5:5011.
Tam et al. Mobile DNA           (2019) 10:32 Page 13 of 14
141. Benayoun BA, Pollina EA, Singh PP, Mahmoudi S, Harel I, Casey KM, et al.
Remodeling of epigenome and transcriptome landscapes with aging in
mice reveals widespread induction of inflammatory responses. Genome Res.
2019;29(4):697–709.
142. Ji A-L, Zhang X, Chen W-W, Huang W-J. Genetics insight into the
amyotrophic lateral sclerosis/frontotemporal dementia spectrum. J Med
Genet. 2017;54(3):145–54.
143. Chen H, Kankel MW, Su SC, Han SWS, Ofengeim D. Exploring the genetics
and non-cell autonomous mechanisms underlying ALS/FTLD. Cell Death
Differ. 2018;25(4):646–60.
144. Nguyen HP, Van Broeckhoven C, van der Zee J. ALS genes in the genomic
era and their implications for FTD. Trends Genet. 2018;34(6):404–23.
145. Pattamatta A, Cleary JD, Ranum LPW. All in the family: repeats and ALS/FTD.
Trends Neurosci. 2018;41(5):247–50.
146. Tica J, Lee E, Untergasser A, Meiers S, Garfield DA, Gokcumen O, et al. Next-
generation sequencing-based detection of germline L1-mediated
transductions. BMC Genomics. 2016;17:342.
147. Pradhan B, Cajuso T, Katainen R, Sulo P, Tanskanen T, Kilpivaara O, et al.
Detection of subclonal L1 transductions in colorectal cancer by long-
distance inverse-PCR and Nanopore sequencing. Sci Rep. 2017;7(1):14521.
148. Faulkner GJ, Billon V. L1 retrotransposition in the soma: a field jumping
ahead. Mob DNA. 2018;9:22.
149. Flasch DA, Macia A, Sanchez L, Ljungman M, Heras SR, García-Pérez JL, et al.
Genome-wide de novo L1 retrotransposition connects endonuclease
activity with replication. Cell. 2019;177(4):837-51.
150. Steranka JP, Tang Z, Grivainis M, Huang CRL, Payer LM, Rego FOR, et al.
Transposon insertion profiling by sequencing (TIPseq) for mapping LINE-1
insertions in the human genome. Mob DNA. 2019;10:8.
151. Sultana T, van Essen D, Siol O, Bailly-Bechet M, Philippe C, Zine El Aabidine
A, et al. The landscape of L1 retrotransposons in the human genome is
shaped by pre-insertion sequence biases and post-insertion selection. Mol
Cell. 2019;74(3):555–570.e7.
152. Goerner-Potvin P, Bourque G. Computational tools to unmask transposable
elements. Nat Rev Genet. 2018;19(11):688–704.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Tam et al. Mobile DNA           (2019) 10:32 Page 14 of 14
